Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enhertu in HER2-expressing advanced solid tumors
NCT04294628Phase 1Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Sep 2020
- Primary completion
- Sep 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of trastuzumab deruxtecan in Solid neoplasm and HER2-positive breast carcinoma, sponsored by National Cancer Institute. Started Sep 2020; status: active, not recruiting.
02
Drugs
trastuzumab deruxtecan
03
Conditions
Solid neoplasmHER2-positive breast carcinoma
Beyond the preview
Go deeper on NCT04294628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04294628.